A bottom-up approach was used to design synthetic consortia for the targeted production of PHACOS (an antimicrobial polyhydroxyalkanoate (PHA) derivative), butanol, and H2, from CO2 (carbon source) and light (energy source). These communities are much simpler than natural ones and include organisms that have been engineered for the production of target molecules. In these consortia, metabolic engineering is being used to (i) introduce the production pathways of interest not found in natural strains, and (ii) implement the necessary control measures (e.g., removing competing pathways, enzymatic bottlenecks, etc.) for adjusting the consortium to desired phenotypes.
The biosynthesis of acetate from CO2 and light was optimised through metabolic engineering of the cyanobacterium Synechocystis PCC 6803. Insertion of a phosphoketolase (PK) in the acs gene resulted in an enhanced Calvin-Benson-Bassham cycle and 40-fold higher acetate production. Further overexpression of a phosphotransacetylase (Pta) led to an increase of 80-fold, reaching an acetate production of 2.3 g/L. A synthetic consortium, based on the Synechocystis PCC 6803 strain that secretes acetate and a phototrophic bacterium Rhodopseudomonas palustris growing on the formed acetate, enabled the production of biohydrogen and fatty acids through nitrogen and carbon dioxide fixation. Elemental balance confirmed carbon capture and nitrogen fixation into the consortium. Proteomic analysis indicated acetate exchange and light-dependent regulation of metabolic activities.
We aimed to obtain a superior Farmer strain able to provide high level of sucrose from CO2 and light as feedstock for Labour heterotrophic modules. Starting with the sucrose overproducer Synechococcus strain SBG363 (Patent WO 2021/148693 A1), we designed a further optimisation strategy, by applying strain-designing algorithms and the metabolic model of Synechococcus iJB7852, based on deletion of key genes involved in sucrose competing pathways. A total of three genes were identified and deleted in wild-type Synechococcus, which cause growth impairments, especially the glycogen synthase knock-out (∆glgA). Finally, the sucrose overproducing strategy was implemented in the triple mutant and sucrose production was assayed. Preliminary results indicated that a deeper understanding of sucrose and glycogen metabolism in Synechococcus is needed to further optimise sucrose production.
Using a rational, model-driven metabolic engineering approach, we have designed a Pseudomonas putida KT2440 biocatalyst capable of efficiently utilising sucrose-produced by cyanobacteria from CO₂ and light- while enhancing acetyl-CoA levels. These metabolic improvements enable the seamless conversion of acetyl-CoA into bioplastics—specifically, medium-chain-length polyhydroxyalkanoates (PHAs)—without nutrient limitation constraints. Supplementing the growth medium with 6-acetyl-thiohexanoic acid (6-ATH) facilitates the accumulation of up to 70% (g/g CDW) of a high-value functionalised PHA, known as PHACOS, which exhibits antimicrobial activity against pathogens such as Staphylococcus aureus.
Pseudomonas putida biocatalyst accumulating PHACOS